← All trials
NCT04808531
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2021
- Primary completion
- Aug 31, 2023
- Completion date
- Jan 31, 2024
- First posted
- Mar 22, 2021
- Last posted
- Mar 22, 2021
- Enrollment
- 360
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medlab ClinicalLead sponsor
- George Clinical Pty LtdCollaborator
- WriteSource Medical Pty LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.